In this video, we explain Avenna’s core technology, GlyHealth. We explain the current four variants in our development pipeline including, GlyHealth-Index, IBD, SCI, and COVID-19, and expand on GlyHealth-Index and IBD. This video also compares conventional vs glycomic biomarkers for early detection and treatment personalisation of inflammatory disease.
In our presentation at this renowned tech conference, our CEO discusses the burden of chronic inflammatory diseases (CIDs) and limitations in CIDs diagnostic procedures. . Additionally, this presentation explains how Avenna medical technology aims to reliably detect and predict future CIDs using molecular signals from blood samples.